A randomized phase II trial of metronomic oral vinorelbine  plus cyclo­phos­phamide and capecitabine (VEX) versus weekly paclitaxel as first-line or second-line treatment in patients with ER-positive/HER2-negative advanced or metastatic breast cancer

Study Chair
Dr. Elisabetta Munzone (IEO Milan, Italy)

Statistician
Subrina Farah

Lead Trial Coordinator
Holly Shaw

Trial contact in Italy:
Raffaella Ghisini, MSc

Data Manager
Karolyn Scott

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Trial Monitors
Giuseppe Achille, Daniela Celotto, Carmen Comune

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Date of Activation
July 25, 2016

Targeted Accrual
160

International Breast
Cancer Study Group

Effingerstrasse 40
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: ibcsgcc@ibcsg.org

Member Login